The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.

Authors

Domenico Albano, Stephane Chauvie, Alessio Rizzo, Francesco Bertagna, Beatrice Casadei, Umberto Vitolo, Alessandra Tucci, Pier Luigi Zinzani, Luca Guerra

Published in

Clinical lymphoma, myeloma & leukemia. Jun 15, 2026. Epub Jun 15, 2026.

Abstract

The prognostic value of interim 18F-fluorodeoxyglucose positron emission tomography/computed tomography (iPET/CT) in diffuse large B-cell lymphoma (DLBCL) remains a subject of debate due to inconsistencies in timing and interpretation. This updated systematic review and meta-analysis aimed to investigate the ability of iPET to predict progression-free survival (PFS). A systematic literature search was conducted across PubMed/MEDLINE, Cochrane, and Embase databases until December 31, 2025. Studies investigating the prognostic value of iPET/CT for PFS in DLBCL were included. Data on complete metabolic response (CMR) rates and hazard ratios (HR) for PFS were pooled using a random-effects model. The pooled CMR rate across 66 articles (9.335 patients) was 67.2% (95% confidence interval [CI]. 63.9%-70.4%), though significant variability (38%-94%) and extreme heterogeneity were observed (I² = 92.45%). Subgroup analysis confirmed that timing influenced these rates: CMR was 63.3% after 2 cycles vs. 74.4% after 4 cycles. Regarding PFS, the pooled HR across 63 studies was 3.05 (95% CI, 2.63-3.54) for a positive iPET. Notably, utilizing a Deauville score (DS) threshold of 5 alone yielded a significantly higher pooled HR of 5.72 (95% CI, 4.35-7.51) with more moderate heterogeneity (I² = 40.7%). In contrast, the prognostic effect of ΔSUV66% was weaker, with a pooled HR of 1.83. Scans performed after 4 cycles (iPET4, HR: 3.20) showed slightly stronger prognostic performance than those after 2 cycles (iPET2, HR: 2.84). Interim PET/CT, particularly when utilizing the DS 5 threshold, is a strong biomarker for identifying high-risk DLBCL patients.

PMID:
42409674
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.